What is the price target for SGMO stock?
11 analysts have analysed SGMO and the average price target is 3.89 USD. This implies a price increase of 1078.05% is expected in the next year compared to the current price of 0.3301.
SANGAMO THERAPEUTICS INC (SGMO) Forecast, Price Target & Analyst Ratings
NASDAQ:SGMO • US8006771062
Current stock price
0.3301 USD
-0.01 (-4.07%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SANGAMO THERAPEUTICS INC (SGMO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 30, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.06
- Revenue Estimate
- 20.706M
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.89
Upside
+ 1,078.05%
From current price of $0.33 to mean target of $3.89, Based on 11 analyst forecasts
Low
$1.26
Median
$2.04
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
17.31%
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for SGMO. The average price target is 3.89 USD. This implies a price increase of 1078.05% is expected in the next year compared to the current price of 0.3301.
The average price target has been revised upward by 17.31% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
SGMO was analyzed by 11 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about SGMO.
In the previous month the buy percentage consensus was at a similar level.
SGMO was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-07 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2025-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-18 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-01-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | Truist Securities | Maintains | Buy -> Buy |
| 2025-01-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-31 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-31 | Jefferies | Maintains | Buy -> Buy |
| 2024-12-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 30, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.06
- Revenue Estimate
- 20.706M
- Revenue Q2Q
- 174.22%
- EPS Q2Q
- 44.36%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
13.29%
Next Earnings Summary
SGMO is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.06 USD and the consensus revenue estimate is 20.71M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 111.3M 0.54% | 176.232M 58.34% | 57.8M -67.20% | 60.568M 4.79% | 49.225M -18.73% | 168.64M 242.59% | 211.34M 25.32% | 409.8M 93.91% | 555.29M 35.50% | 733.79M 32.15% | 882.61M 20.28% | 968.24M 9.70% | |
| EBITDA YoY % growth | -189.2M -8.80% | -87.527M 53.74% | -93.041M -6.30% | -45.39M 51.22% | -83.334M -83.60% | -225.42M -170.50% | 113.32M 150.27% | 234.5M 106.94% | 359.04M 53.11% | N/A | N/A | N/A | |
| EBIT YoY % growth | -201.3M -9.82% | -102.592M 49.04% | -98.148M 4.33% | -76.041M 22.52% | -91.316M -20.09% | -4.896M 94.64% | 33.227M 778.66% | 223.45M 572.50% | 355.44M 59.07% | 491.95M 38.41% | 626.18M 27.29% | 702.32M 12.16% | |
| Operating Margin | -180.86% | -58.21% | -169.81% | -125.55% | -185.51% | -2.90% | 15.72% | 54.53% | 64.01% | 67.04% | 70.95% | 72.54% | |
| EPS YoY % growth | -1.25 -0.81% | -1.47 -17.60% | -0.52 64.63% | -0.34 34.48% | -0.28 17.37% | 0.07 123.55% | 0.16 135.85% | 0.71 352.25% | 1.08 53.37% | 1.74 60.35% | 2.15 23.75% | 2.34 8.77% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 44.36% | -0.06 53.86% | -0.06 19.25% | -0.06 44.36% | -0.03 44.45% |
| Revenue Q2Q % growth | 20.706M 174.22% | 20.961M 225.63% | 21.93M 19.80% | 23.103M 3,876.42% | 37.638M 81.77% |
| EBITDA Q2Q % growth | 3.06M 114.65% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 5.559M 121.39% | -14.28M 51.80% | -13.26M 25.74% | -11.22M 68.44% | -7.14M -228.44% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
28.61%
EPS Next 5 Year
27.43%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
39.81%
Revenue Next 5 Year
46.03%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-31.75%
EBIT Next 5 Year
34.36%
SANGAMO THERAPEUTICS INC / SGMO Forecast FAQ
What is the next earnings date for SGMO stock?
SANGAMO THERAPEUTICS INC (SGMO) will report earnings on 2026-03-30, after the market close.
Can you provide the consensus estimates for SANGAMO THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of SANGAMO THERAPEUTICS INC (SGMO) is -0.06 USD and the consensus revenue estimate is 20.71M USD.
How many analysts cover SANGAMO THERAPEUTICS INC (SGMO) stock?
The number of analysts covering SANGAMO THERAPEUTICS INC (SGMO) is 11.